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approximately 2 hours.6 This protein consists of 2 sub-
units: S-100αα is predominantly found in the heart,
kidney, and striated muscles, S-100αβ in glial cells, and
S-100ββ in astrocytes and Schwann cells. Thus the β
subunit of S-100 is specific for neuronal tissue. Neuron-
specific enolase (NSE) has a molecular weight of 78
kDa and is mainly located in the cytoplasm of
endocrine tissues and axonal processes.7 Release of
both proteins into peripheral blood suggests neuronal
injury changing both cell membrane integrity and per-
meability of the blood-brain barrier. To date, elevation
of S-100β and/or NSE in peripheral blood has been
reported in patients with a variety of cerebral lesions,
including head injury,8,9 multiple sclerosis,10 status
epilepticus,11,12 brain tumors,13 and stroke,14-18 as well
as after circulatory arrest19 and cardiac operations.20-24
Several of the above reports; suggested a clinical rele-
vance of both proteins in predicting size of cerebral
lesions and/or functional outcome.8,9,14-17,23-25
We undertook this study to evaluate the clinical rele-
vance of S-100β and NSE serum levels in patients
undergoing elective cardiac operations. Additionally,
the time course of potential changes in postoperative
D espite substantial methodologic improvements overthe past decades, cardiac surgery with extracorpore-
al circulation remains a hazard to the brain. Incidences
of postoperative stroke and adverse cerebral outcomes
were recently reported as 2%1 and 6.1%,2 respectively;
the prevalence of postoperative neuropsychologic
deficit thereby is far higher,3-5 reaching values of 79%3
in single studies.
S-100 is an acidic calcium-binding protein, with a
molecular weight of 21 kDa and a biologic half-life of
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levels of both proteins was examined to evaluate the
sampling time associated with the best predictive value
for adverse neurologic outcomes.
Patients and methods
Patients. A total of 190 consecutive patients, 131 men and
59 women, aged 63 ± 1 years (mean ± standard error), under-
going elective cardiac surgery for coronary artery bypass
grafting (CABG, n = 147), valve replacement (n = 29), or
both (n = 14), were enrolled in this study after informed con-
sent had been obtained.
The presence of peripheral vascular disease, diabetes melli-
tus, or arterial hypertension was documented in all cases. Left
ventricular ejection fraction was evaluated during transtho-
racic echocardiography. Preoperative neurologic assessment
included detailed clinical examination and screening of the
brain-supplying arteries by means of extracranial continuous
wave Doppler (n = 165) and/or duplex studies (n = 47).
Carotid disease was classified as mild (stenosis < 50%), mod-
erate (stenosis between 50% and 69%), severe (stenosis
between 70% and 99%), or occlusion. In addition, duration of
cardiopulmonary bypass (CPB), reperfusion, and total dura-
tion of the operative procedure (defined as time between skin
incision and skin closure) were documented.
Neurologic assessment. For the purposes of the present
study, all patients were neurologically assessed before the
operation as well as on the fifth postoperative day. Patients
referred to the neurologic service because of acute onset of
neurologic symptoms were additionally evaluated on the day
of referral and on subsequent occasions depending on their
clinical course. Outcome was classified as type I (uncompli-
cated), type II (confusion, agitation, disorientation, or epilep-
tic seizures), or type III (stroke, stupor, or coma). Patients
with types II and III outcomes were neurologically reassessed
before discharge and, in patients with persisting deficit, also
in the fourth postoperative week. Cranial computed tomogra-
phy (CCT) was routinely performed in all patients with type
III and in selected patients with type II outcomes on the sec-
ond postoperative day.
S-100β and NSE evaluation. Venous blood was drawn
before the operation and then daily in the first 5 postoperative
days, immediately centrifuged at 4000g for 10 minutes, and
stored at –30°C until batch evaluation. Serum S-100β and
NSE levels were measured by commercially available, mono-
clonal, 2-site immunoluminometric assays (LIA-mat and
Sangtec 100 [S-100β] and LIA-mat NSE and Prolifigen
[NSE], Sangtec Medical AB, Bromma, Sweden). Visibly
hemolyzed samples were not analyzed for NSE because
hemolysis elevates NSE levels.26 Detection limits for S-100β
and NSE were 0.1 µg/L and 0.5 ng/L, respectively. In cases in
which S-100β levels were under the detection level, S-100β
values were set at 0.1 µg/L.
In addition to the aforementioned protocol, venous blood
was drawn serially during the first 24 hours after the operation
(at 3, 6, 12, and 24 hours) in 10 patients to evaluate potential
short-term changes in S-100β and NSE serum levels.
Surgical procedure. Midazolam and fentanyl dihydro-
gencitrate were used for anesthesia induction, pancuronium
as a muscle relaxant, and isoflurane as an inhalation anes-
thetic. Surgery was performed under normothermic bypass
(35°C-37°C) with membrane oxygenators (COBE CML Duo,
COBE Cardiovascular Inc, Denver, Colo, and Dideco D 703
Compactflo, Dideco, Mirandola, Italy) with the tubing sys-
tem including an arterial line filter (COBE 40 µ). A nonpul-
satile blood flow pump was used (Stoeckert S3, Stoeckert,
Germany). Temperature was measured intranasally, as well as
in the pulmonary vein and in the arterial and venous lines of
the extracorporeal system. Alpha-stat was used for pH main-
tenance.
Statistical analysis. Normally distributed data were
expressed as mean ± standard deviation and compared with a
2-sample t test or 1-way analysis of variance; non-normally
distributed data were expressed as median and 95% confi-
dence intervals (CI) and were compared by the Mann-
Whitney U, Kruskal-Wallis, or Wilcoxon tests as appropriate.
Correlations of nonparametric data were examined by means
of the Spearmann rank test; the χ2 test was used for compar-
ison of frequencies. Relation between S-100β and NSE lev-
els and operative parameters (duration of CPB, reperfusion,
and total operation time) was assessed by means of linear
regression analysis. Receiver-operating characteristics (ROC)
curves27 were used to evaluate the optimal cutoff values of S-
100β and NSE in predicting postoperative neurologic deficit.
Multivariable logistic regression analysis was performed
to evaluate the value of relevant risk factors and S-100β and
NSE levels for predicting postoperative adverse neurologic
outcomes. The following factors were included in this analy-
sis: age; sex; presence of hypertension, diabetes mellitus,
peripheral vascular disease, or carotid disease; history of
previous stroke or previous cardiac surgery; left ventricular
ejection fraction; duration of bypass, reperfusion, and total
operation time; and serum levels of S-100β and NSE on the
first postoperative day. Concerning S-100β and NSE, the
cutoff values evaluated through ROC curves were used in
this analysis. Thus the odds ratio for adverse neurologic out-
comes when S-100β and/or NSE exceeded a certain value
were evaluated. Initial analysis was performed, including all
potentially relevant factors, with a probability limit of 10%
(P < .1). Subsequently, parameters failing to reach signifi-
cance were excluded by means of conditional backward
selection, and the odds ratios for remaining parameters were
recalculated. Two models were used: model 1 evaluated the
predictive value of relevant parameters in distinguishing
between type I and type II/III outcomes and model 2
between type I/II and type III outcomes. Additionally, a sep-
arate logistic regression model was calculated; this model
evaluated the probability of adverse neurologic outcome
(type II or III outcome) depending on the S-100β serum lev-
els on the first postoperative day and relevant risk factors as
evaluated in the initial multilinear regression analysis. S-
100β values were not dichotomized but rather retained as
continuous values for the purposes of this model. Bonferroni
correction was applied where appropriate. 
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Results
Patient characteristics. Prevalence of relevant risk
factors is listed in Table I. Carotid disease was mild in
10, moderate in 4, and severe in further 4 patients, and
a carotid occlusion was diagnosed in 2 patients. Eight
patients had had a stroke between 6 months and 5 years
before admission; this was ischemic in 7 and hemor-
rhagic in 1 patient. Multiple ischemic strokes had
occurred in 2 patients.
Seven, 59, 72, and 9 patients underwent CABG for 1,
2, 3, or 4 grafts, respectively. The aortic valve was
replaced in 24, the mitral in 4, and both valves in 1
patient. In the group undergoing both procedures, the
aortic valve was replaced in 10 patients (1 graft, n = 5;
2 grafts, n = 3; 3 grafts, n = 2), the mitral in 2 (2 grafts
in both cases), and both valves in 2 patients (1 and 2
grafts). Patients undergoing both CABG and valve
replacement were significantly older than the remain-
ing patients. Additionally, patients undergoing CABG
were older than those undergoing valve replacement
(Table II). Total duration of the operative procedure
was significantly longer in patients undergoing both
CABG and valve replacement, followed by those
solely undergoing CABG or valve replacement. The
same was true for duration of CPB and reperfusion
(Table II).
Table I. Prevalence of hypertension, diabetes mellitus, peripheral artery disease, and carotid artery disease and
duration of bypass, reperfusion, and total duration of operative procedure depending on postoperative outcome
Type I P1 Type II P2 Type III P3 P
N 154 26 10
Age (y)* 62 ± 8 .02‡ 67 ± 8 1.00‡ 69 ± 11 .05‡ .05§
Hypertension 62 (40%) .98II 11 (42%) .56II 6 (60%) .37II .47II
LVEF (%)* 62 ± 1 .38‡ 56 ± 4 .87‡ 50 ± 3 .07‡ .03§
History of cardiac surgery 4 (3%) .72II 1 (4%) .49II 1 (10%) .22II .47II
Diabetes 49 (32%) .03II 14 (54%) .46II 4 (40%) .59II .10II
Peripheral artery disease 30 (19%) .16II 2 (8%) .31II 2 (20%) .97II .37II
Carotid disease 17 (11%) .61II 2 (8%) .82II 1 (10%) .92II .86II
History of stroke 3 (2%) .02II 4 (15%) .68II 1 (10%) .59II .004II
Bypass (min)† 95 [90-100] .0001¶ 148 [118-185] .22¶ 139 [100-264] .01¶ .0001#
Reperfusion (min)† 33 [31-36] .001¶ 51 [40-72] .10¶ 49 [38-133] .005¶ .0001#
Total OP (min)† 193 [185-201] .0001¶ 270 [225-345] .41¶ 257 [197-361] .02¶ .03#
Carotid disease, Unilateral or bilateral stenosis of the internal carotid artery > 50%; LVEF, left ventricular ejection fraction as assessed before the operation; Total
OP, total operation time.
*Data expressed as mean ± standard deviation.
†Data expressed as median and 95% confidence intervals. P1, Type I versus type II; P2, type II versus type III; P3, type III versus type I (‡2-sample t test, ¶Mann-
Whitney test, and IIχ2 test); P group comparison using 1-way analysis of variance§ and Kruskal-Wallis tests.#
Table II. Duration of bypass, reperfusion, total duration of operative procedure, and prevalence of adverse neuro-
logic outcomes depending on procedure type in 190 patients undergoing cardiac surgery
CABG P1 VR P2 CABG/VR P3 P
N 147 29 14
Age (y)* 64 ± 8 .05‡ 59 ± 11 .001‡ 68 ± 5 .01‡ .005§
CPB (min)† 96 [91-101] .20II 103 [94-113] .0001II 154 [134-176] .0001II .0001¶
Reperfusion (min)† 36 [34-39] .03II 30 [26-36] .001II 49 [40-60] .005II .001¶
Total OP (min)† 198 [190-208] .92II 195 [180-219] .005II 265 [223-295] .001II .003¶
Type II 19 .55# 2 .02# 5 .02# .05#
Type III 4 .01# 2 .02# 4 .002# .001#
S-100β 1 postop (µg/L)† 0.4 [0.3-0.5] .42II 0.3 [0.2-0.5] .0002II 1 [0.6-2.6] .0005II .0001¶
NSE 1 postop (ng/L)† 13.2 [12.3-14.1] .005II 16.5 [14.3-18.9] .01II 25.6 [19.5-32] .0001II .0001¶
S-100β 2 postop (µg/L)† 0.3 [0.2-0.3] .68II 0.3 [0.2-0.4] .005II 0.7 [0.5-1.8] .0002II .001¶
NSE 2 postop (ng/L)† 10.7 [9.9-11.6] .002II 14.8 [11.8-17.4] NSII 19.6 [15.8-25.3] .0001II .0001¶
CABG, Coronary artery bypass grafting; VR, valve replacement; CABG/VR, coronary artery bypass and valve replacement; CPB, cardiopulmonary bypass; Total OP,
total duration of operative procedure.
*Data expressed as mean ± standard deviation.
†Data expressed as median and 95% confidence intervals. P1, CABG versus VR; P2, VR versus CABG/VR; P3, CABG versus CABG/VR (‡2-sample t test, IIMann-
Whitney test, and #χ2 test); P group comparison using 1-way analysis of variance§ and Kruskal-Wallis tests¶).
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Outcome. Type II and III outcomes were observed in
26 (13.7%) and 10 (5.3%) patients, respectively.
Significant differences in the incidence of neurologic
complications in relation to the different operative pro-
cedures were noted (Table II). Disorientation, confu-
sion, and agitation were the main symptoms in patients
with type II outcomes; epileptic seizures were observed
in 1 patient and myoclonic seizures in 2 patients.
Symptoms subsided 4 ± 0.5 days after the operation
(minimum 2 days, maximum 15 days) in all but 1
patient, in whom psychiatric referral was necessary.
This patient was discharged 8 weeks later without any
residual deficit. CCT scans were performed in 7 patients
with type II outcomes on the second (n = 5) or third (n
= 2) postoperative day and revealed marked subcortical
atrophy in 5 and normal findings in 2 patients.
Five of the 10 patients with a type III outcome died.
The cause of death was neurologic in 3 patients (brain
swelling through ischemic infarction in all cases), mul-
tiple organ failure in 1, and cardiogenic shock in a fur-
ther patient, who died on the second postoperative day.
Creatinine levels were within normal range (<100
µmol/L) in 5 of the 10 patients with a type III outcome,
whereas mild or moderate elevations were evident in
the remaining patients (maximum values of 277, 238,
219, 181, and 137 µmol/L on the third, fourth, second,
first, and second postoperative days, respectively).
Deficit on discharge was mild in 2 patients (ataxia and
discrete weakness of the right arm in 1 patient and dis-
crete hemiparesis with complete functional indepen-
dence in the other), moderate in 2 (moderate hemipare-
sis needing help for daily activities), and severe in 1
patient (severe hemiparesis, completely dependent).
CCT scans revealed multiple territory infarcts in 5
patients (bilateral middle cerebral artery, n = 1; middle
and anterior cerebral arteries, n = 2; bilateral posterior
cerebral artery, n = 1; middle and posterior cerebral
arteries, n = 1) and single territory infarcts in 3 patients
with type III outcomes (complete territory of the mid-
dle cerebral artery, n = 1; incomplete territory of the
middle cerebral artery, n = 2). Repeat CCT scans were
performed 2 to 4 days later in all patients and con-
firmed the initial findings. CCT of 1 patient with mod-
erate hemiparesis disclosed no pathologic findings on
the second postoperative day, and the test was not
repeated. No CCT scan was performed in the patient
who died on the second postoperative day. Infarction of
the complete middle and anterior cerebral arterial terri-
tory was evident on necropsy. No watershed infarcts
were diagnosed in any case.
S-100β and NSE. A total of 12 scheduled samples
(1%) were not obtained, and a further 25 NSE samples
(2.1%) were discarded because of hemolysis. Eleva-
tions in the serum levels of both proteins were observed
in 9 of 10 patients in whom blood was serially drawn
during the first 24 postoperative hours. These reached
statistical significance 3 hours after the operation and
remained significantly elevated until the second post-
operative day (Fig 1). Outcome was uncomplicated in
all 10 patients.
Fig 1. Time course of S-100β and NSE levels at 3, 6, and 12 hours and in the first 5 postoperative days in 10
patients with uncomplicated postoperative outcome. Data are expressed as median, and error bars represent 95%
confidence intervals.
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Serum S-100β and NSE levels were significantly
higher in patients undergoing both CABG and valve
replacement than in the remaining patients throughout
the postoperative period. No significant differences
were evident when comparing patients undergoing
CABG and those undergoing surgery for valve replace-
ment (Table II).
Linear regression analysis revealed a significant rela-
tion between CPB duration and S-100β and NSE lev-
els, reaching its highest values for S-100β on the sec-
Fig 2. A, Linear regression between CPB duration and S-100β levels in 190 patients undergoing cardiac surgery.
Interrupted lines represent 95% confidence intervals. r2 was 0.16 and Sy.x 0.62. The equation best matching the
data was S-100β (µg/L) = –0.3 + 0.007 × CPB duration (minutes). B, Linear regression between CPB duration
and NSE levels in the first postoperative day in 190 patients undergoing cardiac surgery. Interrupted lines repre-
sent 95% confidence intervals. r2 was 0.16 and Sy.x 8. The equation best matching the data was NSE (ng/L) =
7.4 + 0.08 × CPB duration.
A
B
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ond postoperative day (r = 0.41, P < .0001) and for
NSE on the first postoperative day (r = 0.40, P < .0001)
(Fig 2, A and B).
Preoperative median S-100β and NSE levels were 0.12
µg/L (95% CI 0.11-0.13 µg/L) and 7 ng/L (95% CI 6.4-
7.7 ng/L), respectively. A significant increase in the
median serum levels of both proteins was observed in all
patients on the first postoperative day (S-100β: 0.12
A
B
Fig 3. A, Time course of S-100β levels preoperatively (day 0) and in the first 5 postoperative days in neurologi-
cally asymptomatic patients (type I outcome), patients with postoperative confusion, agitation, and disorientation
(type II outcome), and patients with postoperative stroke, stupor, or coma (type III outcome). Data are expressed
as median, and error bars represent 95% confidence intervals. B, Time course of NSE levels preoperatively (day
0) and in the first 5 postoperative days in neurologically asymptomatic patients (type I outcome), patients with
postoperative confusion, agitation, and disorientation (type II outcome), and patients with postoperative stroke,
stupor, or coma (type III outcome). Data are expressed as median, and error bars represent 95% confidence intervals.
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µg/L [95% CI 0.11-0.13 µg/L] vs 0.42 µg/L [95% CI
0.37-0.48 µg/L]; NSE: 7.4 ng/L [95% CI 7-9 ng/L] vs
14.4 ng/L [95% CI 13.5-15.4 ng/L]; both P < .00001,
Mann-Whitney). In patients with an uncomplicated out-
come, the increase of S-100β levels lost significance on
the fourth postoperative day; NSE levels remained sig-
nificantly elevated throughout the postoperative period.
In patients with type II/III outcomes, S-100β and NSE
levels were significantly higher than those in patients
with a type I outcome and than preoperative values
throughout the postoperative period (Fig 3, A and B).
Levels of both proteins were significantly higher in asso-
ciation with type III as compared with type II outcomes;
this difference was statistically significant throughout
the postoperative period, with the exception of NSE lev-
els on the fourth postoperative day (Fig 3, A and B).
Within the group of patients with type III outcomes,
peak values for S-100β and NSE were higher in the
patients who died than in those who survived (S-100β
3.4 µg/L [95% CI 2-20 µg/L] vs 1.4 µg/L [95% CI 0.6-
4.3 µg/L]; NSE: 31 ng/L [95% CI 17-40 ng/L] vs 28
ng/L [95% CI 13-46 ng/L]; P = .07 and .75, Mann-
Whitney test).
The optimal cutoff values of S-100β and NSE for
predicting adverse neurologic outcomes were evaluated
by means of ROC curves (Fig 4, A and B). Both NSE
and S-100β levels demonstrated high sensitivity and
specificity in identifying patients with type III out-
comes. Identification of all patients with adverse out-
comes (types II and III) was also feasible, sensitivity
and specificity of S-100β levels being markedly higher
than those obtained with the use of NSE levels. On the
other hand, S-100β levels below 1.1 µg/L on the first
postoperative day had a specificity of 97.4% in exclud-
ing adverse neurologic outcomes. Similar results were
obtained regarding NSE levels on the first postopera-
tive day (86% of patients with a type I outcome had
NSE levels < 20 ng/L).
The first multivariable linear regression model iden-
tified bypass duration, left ventricular ejection fraction,
A B
Fig 4. ROC curves for evaluation of the optimal cutoff values of A, S-100β and B, NSE in the differentiation
between patients with an uncomplicated outcome (type I) and those with type II or type III outcomes (upper
curve) and between patients with types I/II and those with type III outcomes (lower curve). Optimal cutoff val-
ues and derived specificity and sensitivity are displayed. 
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increase of S-100β values > 0.5, and combined increase
of S-100β values > 0.5 and NSE values > 14.4 as sig-
nificant predictors for type II or type III outcomes. The
model was then recalculated with the use of only these
parameters. The results are listed in Table III. Similar
results were obtained when the model was recalculated,
including only patients undergoing CABG. It must be
noted that the observed lack of influence of previous
stroke or cardiac surgery could be due to the low num-
ber of patients (Table I).
The second multivariable linear regression model
could not be calculated because of the low number of
type III outcomes. Univariate analysis demonstrated a
high predictive value for both S-100β > 0.85 µg/L
(odds ratio 68.14, 95% CI 8.2-565.16, P < .0001) and
NSE > 18.3 ng/L (odds ratio 7.3, 95% CI 1.59-33.44, P
< .01). Because of the low number of cases, no adjust-
ment for bypass duration or left ventricular ejection
fraction was performed in these cases.
The formula derived by the third multivariable linear
regression model was as follows:
Probability = 1/(1/[exp (3.67 × S-100β [µg/L] + 
0.021 × bypass duration [min] – 
0.0239 × LVEF [%] – 4.538)])
whereby mean bypass duration was calculated as
105.93 minutes and mean left ventricular ejection frac-
tion (LVEF) as 60.49%. S-100β values > 1.4 µg/L were
related to an 80% probability of adverse neurologic
outcome; this reached 90% when S-100β levels
exceeded 1.7 µg/L (Fig 5).
Discussion
A basic methodologic difference between the present
study and previous reports is the choice of sampling
period. We assumed that elevated S-100β and NSE lev-
els in the early postoperative hours would not provide
relevant prognostic information concerning neurologic
deficit; therefore we performed the first postoperative
blood sampling 24 hours after the operation, instead of
acquiring blood samples during the operation as well as
within the first 4 to 24 postoperative hours, as was the
case in most recent studies. The significantly elevated
S-100β and NSE serum levels in the first 24 postoper-
ative hours observed in 9 of the 10 patients with an
uncomplicated outcome (Fig 1) in this study support
this assumption. Identical results were reported by
Taggart and associates21: Elevated S-100β serum levels
were found in 21 of 43 patients 4 hours after skin clo-
sure; none of these patients had neurologic symptoms.
Furthermore, both S-100β and NSE were reported to
reach their peak increase 2 to 3 days after middle cere-
bral artery occlusion in an animal model28 and after
ischemic stroke in patient studies,14-17 adding weight to
our methodologic approach.
The high specificity and sensitivity of S-100β serum
levels in predicting adverse neurologic outcome is a
major finding of the present study. Our results suggest
that S-100β levels 24 hours after the operation possess
a sensitivity and specificity of approximately 90% in
identifying patients with cerebral lesions, thus indicat-
ing the need for further examinations. The opposite
statement was also found to be true, as specificity of S-
100β levels in excluding cerebral lesions was 97%.
Additionally, the applied multivariable logistic regres-
sion model demonstrated that S-100β serum levels pos-
sess a high predictive value for prediction of adverse
neurologic outcomes, independently of other relevant
risk factors. Serums levels of NSE were shown to pos-
sess a lower predictive value; sole increase of NSE was
Fig 5. Probability for adverse neurologic outcome (types II
and III) depending on S-100β values on the first postopera-
tive day, calculated by means of a logistic regression model.
Table III. Evaluation of independent predictors of
adverse neurologic outcomes by means of multiple
logistic regression analysis with backward selection
procedure in 190 patients undergoing cardiac surgery
Variables Odds ratio 95% CI Probability
LVEF (%) 0.97 0.94-1 .07
Bypass duration (min) 1.02 1-1.04 .006
S-100β ≤ 0.5; NSE ≤ 14.4* 1
S-100β ≤ 0.5; NSE > 14.4* 1.56 0.29-8.28 .6
S-100β > 0.5; NSE ≤ 14.4* 16.22 3.43-76.65 .0004
NSE > 14.4; S-100β > 0.5* 21.79 5-95.06 .00001
LVEF, Left ventricular ejection fraction.
*NSE values in nanograms per liter; S-100β values in micrograms per liter; all
values were evaluated on the first postoperative day.
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not predictive of adverse neurologic outcomes, and
increase of both S-100β and NSE levels only marginal-
ly improved the predictive value of a sole S-100β
increase. The demonstrated superiority of S-100β in
comparison with NSE levels is in agreement with most
previous reports. We did not observe elevated NSE lev-
els in the absence of elevated S-100β levels in any of
the symptomatic patients; thus routine evaluation of
both proteins appears redundant and not cost effective.
The significant postoperative elevation of S-100β
and NSE serum levels irrespective of neurologic out-
come suggests that cardiac surgery almost always
results in brain injury. This remains unnoticed on clin-
ical examination but can readily be detected by neu-
ropsychologic testing.3-5 The close relation observed
for duration of CPB with both elevation of S-100β and
NSE levels and outcome identifies this procedure as
responsible for at least part of the postoperative deficit.
Recent reports suggested a correlation between S-
100β levels and lesion size on CCT.14-16 The size of our
study, as well as the low number of patients with focal
neurologic lesions, prohibited such analysis. Interest-
ingly, vascular encephalopathy was diagnosed in 5 of 7
patients with postoperative disorientation who under-
went CCT. This finding is in accordance with the
results of Schmidt and associates,29 who identified ven-
tricular width as the only risk factor for postoperative
encephalopathy. We hypothesize that the pre-existing
encephalopathy in our patients was exacerbated
through microembolism and/or hypoperfusion during
CPB, causing the aforementioned symptoms. We did
not apply stroke scales to characterize functional out-
come in our patients; this was due to the low number of
patients in whom permanent deficit was observed.
We conclude that serum levels of S-100β sampled on
the first postoperative day are valid clinical predictors
for adverse neurologic outcome in patients undergoing
cardiac surgery and might prove useful in assessing the
effect of alternative surgical techniques or neuroprotec-
tive treatment.
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